Safety and time to response of [177Lu]Lu-DOTATATE in patients with newly diagnosed advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Sub-analysis of the phase 3 randomized NETTER-2 study.

被引：0

作者：

Kunz, Pamela L.

Ferone, Diego

Halperin, Daniel M.

Myrehaug, Sten

Herrmann, Ken

Pavel, Marianne

Chasen, Beth

Capdevila, Jaume

Tafuto, Salvatore

Oh, Do-Youn

Yoo, Changhoon

Falk, Stephen

Halfdanarson, Thorvardur Ragnar

Folitar, Ilya

Zhang, Yufen

de Herder, Wouter W.

Singh, Simron

机构：

[1] Yale Sch Med, New Haven, CT USA

[2] IRCCS Policlin San Martino, Genoa, Italy

[3] Univ Genoa, Genoa, Italy

[4] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[5] Univ Toronto, Toronto, ON, Canada

[6] Univ Duisburg Essen, Dept Nucl Med, Essen, Germany

[7] Univ Hosp Essen, German Canc Consortium DKTK, Essen, Germany

[8] Friedrich Alexander Univ Erlangen Nurnberg, Uniklinikum Erlangen, Erlangen, Germany

[9] Vall Hebron Univ Hosp, Barcelona, Spain

[10] Vall Hebron Inst Oncol VHIO, Barcelona, Spain

[11] Ist Nazl Tumori IRCCS, Oncol Clin & Sperimentale Sarcomi & Tumori Rari, Naples, Italy

[12] Seoul Natl Univ, Coll Med, Grad Sch, Seoul Natl Univ Hosp,Canc Res Inst, Seoul, South Korea

[13] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea

[14] Univ Hosp Bristol NHS Fdn Trust, Bristol Haematol & Oncol Ctr, Bristol, England

[15] Mayo Clin, Rochester, MN USA

[16] Novartis Pharma AG, Basel, Switzerland

[17] Novartis Pharmaceut, E Hanover, NJ USA

[18] Erasmus MC, Rotterdam, Netherlands

[19] Erasmus MC Canc Inst, Rotterdam, Netherlands

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4131

引用

页数：1

共 18 条

[11] Genetic profiling analysis design of well-differentiated aggressive grade 2 and 3 gastroenteropancreatic neuroendocrine tumors in the phase III randomized controlled COMPOSE trial.
Halfdanarson, Thorvardur Ragnar
Capdevila, Jaume
Halperin, Daniel M.
Herrmann, Ken
Kong, Grace
Leyden, Simone
Mailman, Josh
Reidy-Lagunes, Diane
Srirajaskanthan, Rajaventhan
Erdo, Mate
Rotger, Amanda
Thevenet, Thomas
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS660 - TPS660
[12] Pivotal phase III COMPOSE trial will compare 177Lu-edotreotide with best standard of care for welldifferentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors
Halfdanarson, Thorvardur Ragnar
Reidy, Diane Lauren
Vijayvergia, Namrata
Halperin, Daniel M.
Goldstein, Grace
Kong, Grace
Michael, Michael
Leyden, Simone
Grozinsky-Glasberg, Simona
Sorbye, Halfdan
Oberg, Kjell E.
Sierras, Cristina
Harris, Philip
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[13] Dual Somatostatin Receptor/18F-FDG PET/CT Imaging in Patients with Well-Differentiated, Grade 2 and 3 Gastroenteropancreatic Neuroendocrine Tumors
Metser, Ur
Nunez, Jose E.
Chan, David
Kulanthaivelu, Roshini
Murad, Vanessa
Santiago, Anna T.
Singh, Simron
JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (10) : 1591 - 1596
[14] Pharmacokinetics and RP2D analysis from ETCTN 10388: A phase I trial of triapine and lutetium Lu-177 dotatate in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Chauhan, Aman
Christner, Susan M.
Beumer, Jan Hendrik
Kunos, Charles
Khurana, Aman
El Khouli, Riham
Weiss, Heidi
Yan, Donglin
Soares, Heloisa P.
Halfdanarson, Thorvardur Ragnar
Li, Daneng
Carson, William Edgar
Evers, Mark B.
Ivy, Percy
Kohn, Elise C.
Rubinstein, Larry
Arnold, Susanne M.
Kolesar, Jill
Anthony, Lowell Brian
Konda, Bhavana
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 648 - 648
[15] ACTION-1 phase Ib/3 trial of RYZ101 in somatostatin receptor subtype 2-expressing (SSTR2+) gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Initial safety analysis
Morris, Michael
Ulaner, Gary A.
Halperin, Daniel M.
Strosberg, Jonathan R.
Mehr, Samuel H.
Li, Daneng
Soares, Heloisa P.
Anthony, Lowell Brian
Kotiah, Sandy Diana
Jacene, Heather
Pavel, Marianne E.
Kunz, Pamela L.
Ferreira, Denis Vasconcelos
Li, Joanne
Ma, Kimberly
Rearden, Jessica
Moran, Susan
Hope, Thomas A.
Singh, Simron
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[16] A prospective randomized, double-blind phase 2 study to evaluate the diagnostic efficacy of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: Compared with 68Ga-DOTATATE
Zhu, W.
Jia, R.
Cheng, Y.
Zhao, H.
Bai, C.
Xu, J.
Yao, S.
Huo, L.
JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 202 - 202
[17] Design of a phase 3, international multicenter, prospective, randomized, double-blind, placebo controlled study assessing the efficacy and safety of lanreotide depot 120 mg in patients with well-differentiated, advanced typical and atypical lung neuroendocrine tumors (NETs)
Reidy-Lagunes, Diane
Wolin, Edward M.
Lowenthal, Susan Pitman
Cox, David
Kulke, Matthew H.
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (02) : S31 - S31
[18] A prospective, multicenter, single-arm, open-label, phase 3 study of Lanreotide Autogel (LAN) in Chinese patients with unresectable, locally advanced or metastatic grade 1 or 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Lu, M.
Li, E.
Cao, D.
Chen, J.
Zhang, N.
Hu, H.
Zou, J. Y.
Shi, X.
Truong, Thanh X. M.
Shen, L.
JOURNAL OF NEUROENDOCRINOLOGY, 2023, 35 : 230 - 230

← 1 2 →